SCHEDULE 13G/A: Perceptive Advisors and Joseph Edelman Maintain Significant 9.9% Stake in Acrivon Therapeutics
Beneficial Ownership Disclosure
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. collectively report a 9.9% beneficial ownership stake in Acrivon Therapeutics, Inc., holding 3,104,139 shares of common stock.
Summary
- Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") have filed an Amendment No. 4 to Schedule 13G regarding their beneficial ownership in Acrivon Therapeutics, Inc.
- The Reporting Persons collectively beneficially own 3,104,139 shares of Acrivon Therapeutics, Inc. Common Stock, representing 9.9% of the class.
- This ownership percentage is based on 31,354,984 shares of Common Stock outstanding as of April 21, 2025, as reported by Acrivon Therapeutics, Inc. in its Definitive Proxy Statement on Schedule 14A filed on April 25, 2025.
- Perceptive Life Sciences Master Fund, Ltd. directly holds the 3,104,139 shares.
- Perceptive Advisors LLC serves as the investment manager to the Master Fund and is deemed to beneficially own these shares.
- Joseph Edelman, as the managing member of Perceptive Advisors LLC, is also deemed to beneficially own these shares.
- All Reporting Persons share both voting power and dispositive power over the 3,104,139 shares.
Sentiment
Score: 6
Explanation: The filing is a standard disclosure of a significant, passive ownership stake by a prominent life sciences investor. It indicates continued confidence in the company by a major shareholder, without providing new operational or financial details that would significantly alter sentiment.
Positives
- Continued significant investment by Perceptive Advisors LLC, a prominent life sciences investment firm, indicates ongoing confidence in Acrivon Therapeutics, Inc.
- The reporting persons collectively hold a substantial 9.9% stake, demonstrating a strong commitment to the company.
Future Outlook
NA
Industry Context
This filing indicates continued significant institutional interest from a major life sciences investment firm, Perceptive Advisors, in Acrivon Therapeutics, a company operating in the biotechnology or pharmaceutical sector. Such sustained high-level ownership by specialized funds is a common feature in the biotech industry, where long-term investment horizons are often required.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holding, potentially signaling confidence from a major investor in the company's long-term prospects.
Key Dates
| Date | Description |
|---|---|
| 04/21/2025 | Date as of which 31,354,984 shares of Common Stock were reported outstanding by Acrivon Therapeutics, Inc. |
| 04/25/2025 | Date Acrivon Therapeutics, Inc. filed its Definitive Proxy Statement on Schedule 14A with the SEC. |
| 04/29/2025 | Date of event which requires the filing of this statement. |
| 05/01/2025 | Date of filing of this Schedule 13G Amendment No. 4. |
Keywords
Acrivon Therapeutics, Perceptive Advisors, Joseph Edelman, Perceptive Life Sciences Master Fund, Schedule 13G, beneficial ownership, common stock, investment management, biotechnology, pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.